Skip to content

Media Library

Explore presentations, webinars and video content from hVIVO’s experts.
Gain deeper insight into our science, capabilities and approach to clinical development.

Contact hVIVO
Categories:
Year:
10 Feb 2026 Accelerating Research with The QX700S Digital PCR Platform
30 Jan 2026 HVIVO PLC - FY25 Trading Update
29 Jan 2026 hVIVO: Staying Resilient and Ready – CEO Mo Khan on 2025 Performance and the Road Ahead
29 Jan 2026 hVIVO beats 2025 EBITDA forecasts, eyes growth in 2026
17 Dec 2025 Unlocking the future of obesity treatment
09 Dec 2025 Disease characteristics & immunological profiles obtained form hVIVO's hMPV human challenge model
28 Nov 2025 Driving Growth in Clinical Research: Thomas Forst on CRS’s New Contracts and Future Focus
19 Nov 2025 hMPV Interview with Guy Boivin & hVIVO's Chief Scientific Officer
11 Nov 2025 hVIVO’s Andrew Catchpole on HMPV & RSV research
23 Sep 2025 Q&A with hVIVO CEO, Mo Khan
23 Sep 2025 hVIVO CEO Mo Khan on H1 2025 results & outlook
23 Sep 2025 HVIVO PLC - Interim Results
22 Jul 2025 Q&A with hVIVO CEO, Mo Khan
22 Jul 2025 hVIVO eyes 2026 growth after strong H1 update
22 Jul 2025 H1 25 Trading Update
02 Jul 2025 Positive Topline Results for hVIVO's client Phase 2b field study
10 Jun 2025 World Vaccine Congress Washington 2025 | Interview with Alex Mann, hVIVO
22 Apr 2025 Key Highlights from hMPV Pilot Human Challenge Trial Study
10 Apr 2025 Q&A with hVIVO CEO, Mo Khan
10 Apr 2025 hVIVO CEO on record FY24 revenue & EBITDA as expansion strategy pays off
10 Apr 2025 Full Year Results 2024
07 Apr 2025 Scientific Poster - Incidental Myocarditis in Healthy Adults Following RSV Inoculation
02 Apr 2025 VP of Clinical Operations on hLAB - Industry Leader in Virology & Immunology
05 Mar 2025 Walk Through Tour Plumbers Row
03 Mar 2025 hVIVO Clinical Site Services in Whitechapel
27 Feb 2025 hVIVO Announces Acquisition of Cryostore
27 Feb 2025 hVIVO CEO Mo Khan on strategic Cryostore acquisition
18 Feb 2025 hVIVO Timeline Video
17 Feb 2025 hVIVO expands hMPV research with £2M deal
17 Feb 2025 Q&A with hVIVO CEO, Mo Khan
10 Feb 2025 Director of Clinical Science on Letter of Intent to Assess ILiAD's Whooping Cough Vaccine Candidate
03 Feb 2025 hVIVO secures RSV trial deal with Inhalon Pharma in the US
03 Feb 2025 hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth
29 Jan 2025 Q&A with hVIVO CEO, Mo Khan
20 Jan 2025 hVIVO CEO on record 2024 revenue and strategic CRS acquisition
29 Jan 2025 Trading Update & Acquisition
27 Jan 2025 hVIVO partners with ILiAD Biotechnologies for pivotal Phase 3 human challenge trial
27 Jan 2025 Addressing the Rising Threat of Whooping Cough
21 Jan 2025 hVIVO secures record £2.7M laboratory services contract, expanding global impact in virology
21 Jan 2025 Q&A with hVIVO CEO, Mo Khan
13 Jan 2025 hVIVO successfully completes pilot characterisation study for hMPV, prepares for challenge trials
13 Jan 2025 hVIVO's hMPV Challenge Model Update
20 Dec 2024 hVIVO Year in Review: Milestones, Growth and 2025 Ambitions
20 Dec 2024 hVIVO Year in Review 2024
10 Dec 2024 hVIVO signs £11.5M RSV trial contract; expands services at new facility
10 Dec 2024 Q&A with hVIVO’s Mo Khan
03 Dec 2024 VaccineNation Interview with Adam French - WVC EU 2024
26 Nov 2024 VaccineNation Interview with Andrew Catchpole - WVC EU 2024
22 Oct 2024 hVIVO's Senior Director of Patient Enrolment & Retention on Canary Wharf Facility
10 Oct 2024 hVIVO's Head of QA on the State-of-the-Art facility at Canary Wharf
08 Oct 2024 Growing your business in a challenging marketplace: a CEO perspective
12 Sep 2024 hVIVO PLC - Interim Results, September 2024
10 Sep 2024 hVIVO CEO discusses record H1 revenue and strategic expansion
10 Sep 2024 Interview with CEO Mo Khan, of hVIVO
04 Sep 2024 Describing the World's Largest Human Challenge Unit
29 Aug 2024 Andrew Catchpole on Human Challenge Trials & Canary Wharf State-of-the-Art facility
22 Aug 2024 Director of Clinical Operations on hVIVO's State-of-the-Art Facility in Canary Wharf
15 Aug 2024 hVIVO at Canary Wharf - Yamin 'Mo' Khan
12 Aug 2024 Capital Markets Day 2024
05 Aug 2024 Opening of the World’s Largest Human Challenge Trial Unit
18 Jul 2024 Canary Wharf Facilities Walk Through Tour
18 Jul 2024 Timeline Video hVIVO
17 Jul 2024 hVIVO achieves record first-half revenue as it expands with new Canary Whart headquarters
17 Jul 2024 Q&A with hVIVO’s Mo Khan
17 Jul 2024 Capital Markets Day 2024
09 Jul 2024 hVIVO Joining the Life Science Hub at Canary Wharf
03 Jul 2024 hVIVO CEO Mo Khan on company's expansion and upcoming capital markets day
12 Jun 2024 Dr Andrew Catchpole on Omicron BA.5 Characterisation Study
03 Jun 2024 Hvivo Q&A: “this contract is important as it opens up new markets”
03 Jun 2024 hVIVO secures £2.5mln contract for Omicron characterisation study
09 May 2024 WVC Washington: Interview with hVIVO's Dr Andrew Catchpole
09 May 2024 hVIVO achieves record revenue and initiates dividend policy following successful year
09 May 2024 Hvivo results Q&A with CEO Mo Khan: “we are very confident we will get to £100m of revenue in 2028”
09 Apr 2024 Full Year Results 2023
13 Mar 2024 Yamin ‘Mo’ Khan, CEO of hVIVO, presents at the UK Investor Magazine Investor Conference at the London Stock Exchange
19 Feb 2024 hVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale
30 Jan 2024 Q&A with hVIVO’s Mo Khan: “£80 million is the highest starting order book in the history of the company"
30 Jan 2024 hVIVO announces record financial performance for 2023; projects strong future growth
30 Jan 2024 hVIVO PLC - Company Presentation
02 Jan 2024 hVIVO secures £6.3 million challenge contract
28 Dec 2023 Year in Review 2023
28 Dec 2023 Ask the Experts: A Deep Dive into Human Challenge Trials
21 Dec 2023 hVIVO year in review: bigger and better
13 Dec 2015 Q&A: hVivo’s Mo Khan on the company’s latest mega-deal
13 Dec 2023 hVIVO secures fresh contract to round out "wonderful" year
25 Sep 2023 Master Investor Sector Focus: Healthcare
20 Sep 2023 hVIVO Canary Wharf Facilities - Adam French
13 Sep 2023 hVIVO PLC - Interim Results Presentation
12 Sep 2023 hVIVO has "the perfect opportunity" after strong first half
12 Sep 2023 Q&A with hVIVO’s Mo Khan
29 Aug 2023 hVIVO announces move to "good facility at a very good price"
29 Aug 2023 Plans for a new larger state-of-the-art facility in Canary Wharf
31 Aug 2023 Developing an Influenza B Human Challenge Model
26 Jul 2023 hVIVO CEO reports on "very strong" H1 2023
26 Jul 2023 hVIVO’s Mo Khan: “We have now got 100% contracted work this year to hit our revenue targets”
26 Jul 2023 hVIVO plc – Trading update H1 2023
25 Jul 2023 hVIVO signs second bespoke human challenge model contract in as many months
25 Jul 2023 hVIVO’s Mo Khan: “the industry is really waking up to the value of human challenge models"
10 Jul 2023 hVIVO targeting the nasty virus no one has heard of
29 Jun 2023 hVIVO to Develop hMPV Human Challenge Model
28 Jun 2023 hVIVO to develop first commercial hMPV human challenge model
15 May 2023 Topra Webinar - Human Challenge Trials: Supporting the development of ‘next generation’ COVID-19 Vaccines
15 May 2023 Tom Scott: The people who get paid to get sick
25 Apr 2023 hVIVO reveals audited results for "transformational" 2022
25 Apr 2023 'Mo' Khan of Hvivo: 2022 was a transformative and order book gives strong visibility into H1 2024
25 Apr 2023 Full Year Results 2022
14 Apr 2023 hVIVO at World Vaccine Congress Washington 2023
02 Mar 2023 hVIVO’s Andrew Catchpole Talks Human Challenge Trials, From COVID-19 to Malaria
06 Feb 2023 hVIVO Asian growth strategy bearing fruit with second 2023 contract win
25 Jan 2023 hVIVO PLC - Investor Presentation
15 Jan 2023 hVIVO announces "record results" for 2022
15 Jan 2023 hVIVO's Mo Khan on the company’s breakthrough year
05 Jan 2023 hVIVO CEO Mo Khan discusses the company's Asia Pacific breakthrough
04 Jan 2023 hVIVO contract the fruit of increasing Asian focus
03 Jan 2023 Year in Review 2022 - hVIVO Group
10 Nov 2022 hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal
02 Nov 2022 Capital Markets Day 2022
08 Sep 2022 Open Orphan's CEO talks through name change and a first half 'full of highlights'
08 Sep 2022 OPEN ORPHAN PLC - 2022 Interim Results - Investor presentation
05 Aug 2022 £6.2m Influenza human challenge study contract - BRR Media
04 Aug 2022 Open Orphan subsidiary hVIVO wins £6.2m Influenza human challenge study contract with US customer
01 Jul 2022 Open Orphan and Vaxart are preparing a world-first human challenge model for omicron oral vaccine
15 Jun 2022 LSX World Congress 2022
14 Jun 2022 hVIVO’s £7.2m RSV Human Challenge Model Contract
07 Jun 2022 Open Orphan’s Yamin Khan talks through its ‘excellent’ results
01 Jun 2022 Open Orphan racks up another ‘first’ with £14.7mln full-service flu contract
19 May 2022 Chief Scientific Officer on Influenza Challenge Study contract Win
09 Mar 2022 London South East Presentation March 2022
08 Mar 2022 Volunteer Recruitment & Laboratory Facilities Expansion – Robin Rogiers & BRR Media
08 Mar 2022 Open Orphan sticks to 2021 earnings guidance as it announces an expansion of its facilities
24 Feb 2022 Open Orphan announce Yamin ‘Mo’ Khan as new CEO
24 Feb 2022 CEO Appointment at Open Orphan
17 Feb 2022 hVIVO hail data on phase 2a study published in New England Journal of Medicine
14 Feb 2022 Adrian Wildfire on hVIVO STRiVE Project
14 Feb 2022 Open Orphan subsidiary hVIVO launch of STRiVE to ‘find out what people are actually suffering from’
02 Feb 2022 CSO Andrew Catchpole on the world’s first COVID-19 Characterisation Study
24 Feb 2022 Executive Chairman Cathal Friel on The world’s first COVID-19 Characterisation Study
02 Feb 2022 Open Orphan present ‘invaluable’ key findings of world’s first COVID-19 characterisation study
24 Jan 2022 hVIVO Malaria Challenge Agent
20 Jan 2022 Cathal Friel on Malaria Human Challenge Agent
21 Dec 2021 Open Orphan hail £5m contract for new flu jab challenge study
21 Aug 2021 Cathal Friel and BRR Media Discuss £8.1m Asthma Human Challenge Study Contract Win
07 Jun 2021 FluCamp Hotel Quarantine Facility – Bedroom Tour
09 Apr 2021 Open Orphan: Global Leader in Human Challenge Vaccine Development | Executive Chairman Cathal Friel
16 Dec 2020 Shares Investor Evening with Cathal Friel December 2020
16 Dec 2021 hVIVO secure MHRA approval to start Codagenix COVID-19 Phase I Vaccine Trial
07 Dec 2020 Open Orphan 2020 Year in Review
20 Nov 2020 COVID-19: UK scientists to infect volunteers with coronavirus in world first vaccine trial
20 Oct 2020 Market Coverage: Tuesday October 20 Yahoo Finance
20 Oct 2020 Young people to be deliberately exposed to Covid-19 to speed up vaccine development
06 Aug 2020 Open Orphan Dual Business Firing on All Four Cylinders
06 Oct 2020 Shares Magazine Investor Evening October 2020
01 Dec 2020 Open Orphan Interim Results Interview 2020
10 Aug 2020 Interview with Proactive Investors following £4M contract with Top 3 Global Pharma company
08 Jun 2020 Coronavirus: I took a COVID-19 antibody test to see if I’d had coronavirus without realising it
11 May 2015 FluCamp – what it is like to participate in a clinical trial
15 Sep 2014 hVIVO on BBC1 2014

About Us

hVIVO is a science led drug development partner operating an integrated ecosystem that unifies specialist clinical sites, advanced laboratories, human challenge expertise, and early drug development consulting. This model enables sponsors to generate rigorous, decision ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials. With world leading capabilities in respiratory and infectious disease, expertise in cardiometabolic areas, and the largest human challenge facilities globally, hVIVO supports a diverse international client base. Its integrated approach provides the clarity, speed, and reliability required to advance new medicines with confidence.  

Press Kit

Access our press kit for essential company information, including corporate overviews, key facts, leadership profiles and brand assets. Designed to support journalists, partners and stakeholders, this resource provides accurate, up-to-date materials to help you tell the hVIVO story with confidence.

Investors

Access hVIVO’s investor hub for the latest financial results, reports, and shareholder information. Stay up to date with company performance, regulatory announcements, and key updates. Visit the investor page to explore detailed insights and resources supporting informed decision-making and a deeper understanding of our growth strategy.

Investor Quick Links

Results Centre

Access all the latest results and presentations

Regulatory News

Learn more

Presentations & Events

Learn more 

Environmental, Social & Governance

Learn more 

Share Price Information

Learn more 

AIM Rule 26

Learn more 

Company Documents

Learn more